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Objective
To test the hypothesis that the baseline clinico-pathological
features of the men with localized prostate cancer (PCa)
included in the ProtecT (Prostate Testing for Cancer and
Treatment) trial who progressed (n = 198) at a 10-year
median follow-up were different from those of men with
stable disease (n = 1409).
Patients and Methods
We stratified the study participants at baseline according to
risk of progression using clinical disease stage, pathological
grade and PSA level, using Cox proportional hazard models.
Results
The findings showed that 34% of participants (n = 505) had
intermediate- or high-risk PCa, and 66% (n = 973) had low-
risk PCa. Of 198 participants who progressed, 101 (51%) had
baseline International Society of Urological Pathology Grade
Group 1, 59 (30%) Grade Group 2, and 38 (19%) Grade
Group 3 PCa, compared with 79%, 17% and 5%, respectively,
for 1409 participants without progression (P < 0.001). In
participants with progression, 38% and 62% had baseline low-
and intermediate-/high-risk disease, compared with 69% and
31% of participants with stable disease (P < 0.001). Treatment
received, age (65–69 vs 50–64 years), PSA level, Grade Group,
clinical stage, risk group, number of positive cores, tumour
length and perineural invasion were associated with time to
progression (P ≤ 0.005). Men progressing after surgery (n =
19) were more likely to have a higher Grade Group and
pathological stage at surgery, larger tumours, lymph node
involvement and positive margins.
Conclusions
We demonstrate that one-third of the ProtecT cohort consists
of people with intermediate-/high-risk disease, and the
outcomes data at an average of 10 years’ follow-up are
generalizable beyond men with low-risk PCa.
Keywords
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Introduction
The Prostate Testing for Cancer and Treatment (ProtecT)
randomized clinical trial (RCT) recruited men aged 50–
69 years and compared the effectiveness of active monitoring
(AM), radical prostatectomy (RP) and radical radiotherapy
(RT). A total of 1643 men with clinically localized prostate
cancer (PCa) agreed to randomization. The primary
intention-to-treat analysis at a median follow-up of 10 years
showed that the rate of overall mortality was ~1%,
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Trial
irrespective of treatment assigned. However, radical treatment
was associated with ~50% reduced disease progression/
metastasis compared with AM (AM 6.3, RT 3.0 and RP 2.4
events per 1000 person-years; P = 0.004) [1].
Treatment decisions for localized PCa rely on patient
stratification for disease progression risk using baseline
clinico-pathological features, risk calculators, physician
counselling and patient preference. Current risk stratifications
are based on a combination of PSA value, clinical tumour
(cT) stage, and biopsy Gleason score/International Society of
Urological Pathology (ISUP) Grade Group [2,3], with
considerable heterogeneity in outcomes within groupings.
We provide a comprehensive characterization of the ProtecT
cohort composition according to risk stratification, as well as
detailed pathological information on participants who received
RP. We reviewed the baseline risk classification of all ProtecT
participants using clinico-pathological features, including
clinical stage, grade at diagnosis and serum PSA levels. The aim
of the present study was to test the hypothesis that the clinico-
pathological features of participants with disease progression
differed from those of participants whose disease remained
stable and that such an analysis may determine potential
features associated with prediction of clinical outcomes.
Methods
Participants and Study Design
The ProtecT trial design, baseline socio-demographic and
median 10-year outcomes have been published elsewhere [1,4–
6]. A total of 2417 men were identified with localized PCa, 1643
of whom agreed to be randomized to AM, RP or RT (74 Gray
in 37 fractions with neoadjuvant androgen deprivation
therapy). AM is a form of active surveillance (AS), comprising
regular PSA tests (>90% of participants received a minimum of
two PSA tests per annum) and clinical review if PSA level rises
≥50% in a 12-month period. In some participants, further
investigations and patient/physician preference triggered
change of management to radical treatment.
Participants who started a protocol treatment within
12 months from randomization were the focus of the present
analysis (1607/1643 men). The participants were categorized
as receiving AM if they were monitored with at least two
PSA tests within 1 year of eligibility (diagnosis), and as
receiving RP if they underwent surgery within 1 year. The RT
group comprised men who received this or similar (e.g.
brachytherapy) within 12 months, and completed treatment
within 15 months (or died before completion).
Risk Status
Participants with localized PCa was defined as low risk if they
had Gleason score 6 (Grade Group 1) and PSA level ≤10 ng/
mL and T1c/T2a disease; intermediate risk if they had
Gleason score 7 (Grade Group 2–3), a PSA level > 10 and
≤20 ng/mL, or T2b disease, and high risk if they had Gleason
score ≥8 (Grade Group ≥4), or PSA > 20 ng/mL, or T2c
disease. Some participants had cT2 disease according to a
previous TNM staging system and so could not be given a
risk score (n = 129).
Pathology
Expert histopathologists reported prostate biopsy and RP
pathology on standardized proformas [7]. Grade Group
values for prostate biopsies were derived using the sum of the
primary Gleason grade and the greater of the secondary or
tertiary Gleason grades, reflecting current practice. Grade
Group values for RP were derived using the sum of the
primary and secondary Gleason grades. Aggregate and
maximum tumour lengths in the core biopsies were measured
in mm. The aggregate tumour length was calculated as the
summation of lengths on the right, left and unknown sides
and targeted biopsy. RP specimens were whole-embedded,
and tumour volume calculated. Surgical margins were
recorded as positive if tumour was seen at an inked margin,
and classified as apical, basal, intraprostatic or extraprostatic
[8]. The ProtecT pathology group performed regular internal
audits of biopsy cores and RP specimens to minimize
assessment variation.
Progression and Metastasis
‘Progression’ was subdivided into two categories: PCa death
and/or metastasis, and ‘other’ progression (change to ≥cT3
disease [extracapsular], indication for androgen deprivation
therapy, ureteric obstruction, rectal fistula, or need for a
urinary catheter due to local tumour growth). Cause of
death was ascertained by an independent cause-of-death
committee [9], and disease-specific deaths were classed as
‘definitely’ or ‘probably’ attributable to PCa. Metastatic
disease was defined as bony, visceral, or lymph-node
metastases on imaging, or PSA > 100 ng/mL. Clinical
progression was defined by the presence of any of the
following: evidence of metastases, or ‘other’ progression (as
defined above). Primary treatment failure after RP was
defined as a PSA ≥0.2 ng/mL 3 months after surgery, and
after RT was defined according to the Phoenix Consensus
Conference recommendations [10].
Statistical Analysis
All analyses were carried out using STATA 15.1 [11]. Cox
proportional hazards models were used, all adjusting for
treatment received and age at randomization, to estimate the
hazard ratio, 95% CIs and P values. Competing risks
regression was carried out as sensitivity analyses, where all-
cause mortality (not including PCa deaths) was included in
© 2020 Crown copyright.
BJU International published by John Wiley & Sons Ltd on behalf of BJU International 507
ProtecT trial risk stratification
the model as a competing risk, using the Fine and Gray
method.
The Cox proportional hazards model and likelihood ratio test
were used to test the interaction between treatment allocation
and each of: baseline Grade Group (1, ≥2); clinical stage
(cT1c, cT2); risk group (low, intermediate/high); age (<65,
≥65 years); and PSA level (<10 ng/mL, ≥10 ng/mL), on time
to progression. The risk classification system, and its ability to
predict progression, was also assessed using sensitivity and
specificity calculations.
The above approach to the analysis was adapted to an
investigation of participants randomized to, and receiving,
RP within 12 months, the risk (hazard ratio) of progression
was compared across surgical pathological features adjusted
for participant age. Where the number of events was too
low to successfully conduct a Cox proportional hazards
model, the log rank test was used. Competing risks
analyses were carried out as sensitivity analyses. Categorical
variables were included in the model using dummy
variables. Ordinal categories were included as continuous
categories to assess linear trend. Upgrading was defined as
an increase from Grade Group 1 at baseline to Grade
Group ≥2 at RP, or moving from Grade Group 2 at
baseline to Grade Group ≥3. Upstaging was defined as
moving from cT1/T2 disease at baseline (ProtecT trial
inclusion criterion) to pT3/T4 at RP.
Study Ethics
Trial approval was obtained from the UK East Midlands
(formerly Trent) Multicentre Research Ethics Committee (01/
4/025). The University of Oxford is the trial sponsor
(University of Sheffield prior to 2009). ProtecT is registered
with Current Controlled Trials (ISRCTN20141297) and
ClinicalTrials.gov (NCT00632983).
Results
ProtecT Cohort Composition
Randomized participants (n = 1643) had a mean age of
62 years, were mainly of white ethnicity (98%), and had a
median PSA level of 4.6 ng/mL. Their clinico-pathological
characteristics have been reported previously [5]. Analysis of
the randomized participants (n = 1643) showed that 34% (n
= 505) had intermediate- or high-risk disease, and 66% (n =
973) had low-risk PCa (Table 1). Of 1643 randomized
participants, 1607 started a protocol treatment within 12
months. Of these, 1208 (75%) had Grade Group 1 disease,
and 1222 (76%) had stage cT1c disease. Amongst participants
with Grade Group 1 disease at diagnosis, 87% were in the
low-risk category at baseline, and 13% had intermediate- or
higher-risk disease.
Baseline Clinico-Pathological Features of
Participants with Disease Progression
Of 1607 participants analysed who received AM, RP or RT
within 12 months, 198 (12%) developed PCa progression
during a median follow-up of 10 years (Table 1). Of the
participants with disease progression, 72% (142/198) received
AM. The progression events included the following: 17 PCa-
specific deaths; 44 participants who developed distant
metastases, and 137 participants who had other clinical
evidence of disease progression (Table 1).
Treatment received, age (65–69 vs 50–64 years), PSA, Grade
Group, cT stage, risk group, number of PCa-involved biopsy
cores, maximum length of tumour (median 5.0 vs 3.0 mm),
aggregate length of tumour (median 8.0 vs 4.0 mm), and
presence of perineural invasion were each associated with
increased disease progression risk (P < 0.001 for each;
Table 1). There was no evidence of an interaction between
Grade Group (Grade Group 1, Grade Group ≥2) and
treatment allocation on time to progression (P = 0.709;
Table 2, Fig. 1). There was no evidence of an interaction
between treatment allocation and PCa stage (Fig. 1), age
group (Fig. 2) or PSA level (Fig. 2). At baseline and
according to risk classification, 63 of 166 participants (38%)
with disease progression had low-risk disease, and 103 (62%)
had intermediate-/high-risk disease, compared with 69% (910/
1312) and 31% (402/1312), respectively, of participants
without progression (P < 0.001). Additional adjustment for all
characteristics in Table 1, excluding those used in the risk
categorization, did not alter these associations (P < 0.001). In
assessing risk group as an indicator of progression, the
prognostic sensitivity for intermediate-/ high- vs low-risk
disease was 62% (103/166), while specificity was 69% (910/
1312). Low-risk disease at baseline suggested that a
participant was unlikely to progress (negative predictive value
94%), but the classification of intermediate and/or high risk
was poor at predicting progression (positive predictive value
20%). Subdividing the groups into low-/ intermediate- vs
high-risk disease led to sensitivity and specificity values of
18% and 91%, respectively.
Radical Prostatectomy Pathology Characteristics
Of men randomized to RP, 397 received their allocated
treatment within 12 months, with 19 developing progression
after surgery. No participant who progressed after surgery
had solely Grade Group 1 disease on RP histopathological
examination, whereas eight participants had Grade Group 2,
seven had Grade Group 3, and four had Grade Group ≥4.
This differed from participants without progression (P <
0.001; Table 3). RP pathological features associated with
progression included pathological Grade Group, stage, largest
tumour volume, lymph node involvement, perineural
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invasion, vascular invasion, any positive margin status, and
disease upstaging (P < 0.05 for each comparison). There was
no evidence that the number of tumours in the prostate was
related to progression. PCa upstaging after surgery was
associated with disease progression (P < 0.001) and there was
weak evidence to suggest an association with histopathological
upgrading (P = 0.059).
Discussion
The baseline characteristics of the 1643 randomized
participants were described previously [1,5], and showed that
76% (n = 1249) of participants had T1c disease, and 77% (n
= 1266) had ISUP Grade Group 1 PCa, suggesting that over
three-quarters of our participants had low-risk disease. This
has led to a perception that the favourable clinical outcomes
at a median follow-up of 10 years were largely driven by the
low-risk nature of the cohort. In the present study, following
a detailed analysis of baseline characteristics according to
disease risk classification, we demonstrate that over one-third
of the ProtecT participants receiving treatment within
12 months had intermediate- or high-risk disease. At
baseline, 25% of participants indeed had ISUP Grade Group
≥2 PCa, but inclusion of PSA and clinical stage in the risk
classification revealed a larger percentage with higher-risk
disease. This therefore provides greater relevance of the
clinical outcomes to participants with intermediate- or
higher-risk PCa than hitherto described, and may improve
management decision-making, along with the ‘trade-off’ that
participants need to consider with their treating clinician.
Analysis of baseline clinical and demographic characteristics
of ProtecT participants demonstrated features associated with
disease progression, including treatment received, age, PSA,
Grade Group, cT stage, risk group category, number of PCa-
involved biopsy cores, maximum tumour length per core,
Table 1 Hazard ratios for disease progression by baseline age and clinical characteristics of participants who commenced prostate cancer treatment
within 1 year (N = 1607).
Characteristic N (%) No progression
(n = 1409)
Progression
(n = 198)
Progression HR
(95% CI); P*
Metastasis or
PCa-specific
death (n = 61)
Metastasis or
PCa-specific death
HR (95% CI); P†
Treatment, n (%)
Active monitoring 628 (39) 486 (77) 142 (23) – 36 (6) –
Radical prostatectomy 488 (30) 462 (95) 26 (5) 0.23 (0.15, 0.35); <0.001 10 (2) 0.37 (0.19, 0.76); 0.006
Radical radiotherapy‡ 491 (31) 461 (94) 30 (6) 0.25 (0.17, 0.38); <0.001 15 (3) 0.54 (0.30, 0.99); 0.048
Age§
Median (IQR) age, years 62.0 (58.0, 66.0) 64.0 (59.0, 67.0) 1.04 (1.01, 1.07); 0.010 65.0 (59.0, 67.0) 1.03 (0.98, 1.09); 0.206
Age group 50–64 years, n (%) 1005 (63) 904 (90) 101 (10) – 29 (3) –
Age group 65–69 years, n (%) 602 (37) 505 (84) 97 (16) 1.59 (1.20, 2.10); 0.001 32 (5) 1.85 (1.12, 3.06); 0.017
PSA
Median (IQR) PSA, µg/L 4.5 (3.6, 6.4) 5.9 (4.3, 8.3) 1.13 (1.09, 1.18); <0.001 5.7 (4.3, 8.2) 1.11 (1.03, 1.18); 0.003
PSA ≤10 µg/L, n (%) 1462 (91) 1298 (89) 164 (11) – 50 (3) –
PSA >10 µg/L, n (%) 145 (9) 111 (77) 34 (23) 2.54 (1.75, 3.69); <0.001 11 (8) 2.27 (1.18, 4.38); 0.014
ISUP Grade Group¶, n (%)
1 1208 (75) 1107 (92) 101 (8) – 28 (2) –
2 296 (18) 237 (80) 59 (21) 3.32 (2.39, 4.61); <0.001 22 (7) 3.31 (2.39, 4.58); <0.001
3+ 103 (6) 65 (63) 38 (37) 8.33 (5.65, 12.26); <0.001 11 (11) 8.54 (5.81, 12.56); <0.001
Clinical stage, n (%)
cT1c 1222 (76) 1100 (90) 122 (10) – 36 (3) –
cT2 385 (24) 309 (80) 76 (20) 2.35 (1.76, 3.14); <0.001 25 (6) 2.30 (1.38, 3.84); 0.001
Risk group **, n (%)
Low 973 (66) 910 (94) 63 (6) – 19 (2) –
Intermediate/High 505 (34) 402 (80) 103 (20) 4.12 (3.01, 5.63); <0.001 31 (6) 4.20 (3.06, 5.77); <0.001
Biopsy cores with cancer, n (%)
1 502 (32) 467 (93) 35 (7) – 12 (2) –
2 328 (20) 288 (88) 40 (12) 1.82 (1.16, 2.87); 0.010 11 (3) 1.41 (0.62, 3.20); 0.411
3+ 759 (48) 637 (84) 122 (16) 2.80 (1.92, 4.08); <0.001 37 (5) 2.26 (1.18, 4.35); 0.014
Perineural invasion, n (%)
No 1263 (80) 1135 (90) 128 (10) – 37 (3) –
Yes 320 (20) 252 (79) 68 (21) 2.49 (1.85, 3.34); <0.001 23 (7) 2.61 (1.55, 4.40); <0.001
Median (IQR) maximum length
in any core, mm (n = 1454)
2.0 (1.0, 5.0) 5.0 (2.0, 7.0) 1.04 (1.02, 1.05); <0.001 5.0 (2.0, 7.0) 1.01 (0.99, 1.04); 0.265
Median (IQR) aggregate length of
tumours, mm (n = 1571)
4.0 (2.0, 10.0) 8.0 (4.0, 18.0) 1.02 (1.02, 1.03); <0.001 7.0 (3.0, 20.0) 1.02 (1.00, 1.03); 0.009
HR, hazard ratio; IQR, interquartile range; ISUP, International Society of Urological Pathology; PCa, prostate cancer. *Cox models for time to progression, adjusting for age at
randomization and treatment received unless covariates being tested. †Cox models for time to metastasis or prostate cancer death, adjusting for age at randomization and treatment
received unless covariates being tested. ‡Includes trial protocol radiotherapy, non-protocol radiotherapy and brachytherapy. §Age at randomization. ¶ISUP Grade Group derived
from sum of primary and highest Gleason grade of secondary and tertiary. **Low if Grade Group = 1 and PSA ≤ 10 ng/mL and T1c/T2a, high if Grade Group ≥ 4 or
PSA> 20 ng/mL or T2c and intermediate if Grade Group = 2/3 or 10 < PSA≤20 ng/mL or T2b.
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aggregate tumour length, and perineural invasion. These
factors were not able to reliably predict progression in
individuals.
The observation that diagnostic biopsy Grade Group was
associated with post-treatment recurrence/progression concurs
with previous evidence [12–15]. However, 53% (105/198) of
ProtecT participants with progression had baseline Grade
Group 1 disease, demonstrating inadequate sampling by PSA
testing followed by 10-core TRUS-guided biopsies. This was
substantiated by the observation that none of the participants
who received RP and progressed had pure Grade Group 1
tumours. It is recognized that true low-risk low-volume
Grade Group 1 PCa does not behave aggressively [16], and
that participants with true Grade Group 1 disease are
‘unnecessarily’ cured by radical intervention. It has been
suggested that Grade Group 1 PCa is not cancerous [17], but
there is evidence that low-grade malignant foci can progress
to lethality [18]. Grade Group 1 lesions may, therefore,
comprise a spectrum of disease, indicating the need to
delineate molecular features associated with disease
progression.
The protocol for PCa detection in ProtecT was designed in
the 1990s, before use of multiparametric MRI (mpMRI)
imaging. The PROMIS and PRECISION studies suggest that
mpMRI aids diagnosis of clinically significant PCa, whilst
reducing over-detection of indolent disease [19,20], albeit
with a small associated false-negative rate [19]. Introducing
pre-biopsy imaging and targeted biopsies, alongside genomic
and other assays, will probably improve diagnosis of clinically
significant disease requiring intervention, improving
outcomes. Molecular-based risk stratification using diagnostic
samples aims to improve performance of risk stratification
tools. Incorporating baseline molecular tumour profiling may
lead to more accurate personalized risk stratification than
conventional clinico-pathological features, but these require
prospective evaluation.
Participants in ProtecT with cT2 disease were more likely to
progress compared with those with cT1 disease, and 29% of
participants with cT2b tumours had extraprostatic extension
at RP. The observation that an increased number of positive
cores in the diagnostic biopsies, and an increased maximum
tumour length, were associated with progression is consistent
with AS cohort evidence [21]. Baseline PSA was higher in
ProtecT participants who progressed compared with those
with stable disease, consistent with PSA being a prognostic
factor for recurrent/lethal PCa after radical treatment [22–24].
Of participants who progressed, 101 had Grade Group 1
disease at baseline, and 28 of these developed metastases and/
or died from PCa, suggesting that transrectal 10-core biopsy
without prior mpMRI (as employed in the ProtecT trial
protocol) probably under-sampled and/ or under-detected
high-grade tumours in at least some participants.
The present study has a number of limitations. First, the
ProtecT trial’s standardized diagnostic pathway of combined
DRE, PSA, and TRUS-guided biopsy over-detects indolent
disease, and under-detects significant disease compared with
mpMRI and targeted biopsies [19,20]. The CAP trial (Cluster
Randomized Trial of PSA Testing for Prostate Cancer)
demonstrated that PSA testing with a single round of
Table 2 Disease progression and prostate cancer death and/or metastasis for clinical and age subgroups by randomized treatment allocation.
[Correction added on 05 March 2020, after first online publication: Table 2 has been amended in this version.]
Variable Category n Clinical progression (n = 204) PCa-specific
death/
metastasis
(n = 62)
Active
monitoring
(n = 545)
Surgery
(n = 553)
Radiotherapy
(n = 545)
P * Active
monitoring
(n = 545)
Surgery
(n = 553)
Radiotherapy
(n = 545)
P
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Age (at
randomization)
Younger
(<65 years)
1034 59 (17) 23 (7) 23 (7) 0.924 12 (4) 7 (2) 11 (3) 0.068
Older (≥65 years) 609 53 (26) 23 (12) 23 (11) 21 (10) 6 (3) 5 (2)
PSA ≤10 ng/mL 1495 94 (19) 34 (7) 41 (8) 0.135 26 (5) 9 (2) 16 (3) 0.187†
>10 ng/mL 148 18 (35) 12 (25) 5 (10) 7 (14) 4 (8) 0 (0)
ISUP Grade
Group‡
1 1237 60 (15) 20 (5) 25 (6) 0.709 14 (3) 6 (1) 9 (2) 0.626
2+ 405 52 (39) 26 (18) 21 (17) 19 (14) 7 (5) 7 (6)
Clinical stage cT1c 1249 71 (17) 28 (7) 28 (7) 0.694 19 (5) 7 (2) 11 (3) 0.867
cT2 393 41 (30) 18 (13) 18 (16) 14 (10) 6 (4) 5 (4)
Risk group§ Low 1021 38 (12) 15 (4) 15 (4) 0.912 9 (3) 5 (1) 7 (2) 0.480
Intermediate/
High
489 55 (33) 26 (16) 22 (14) 18 (11) 6 (4) 6 (4)
ISUP, International Society of Urological Pathology; PCa, prostate cancer. *P values calculated with likelihood ratio interaction test of the null hypothesis of no difference in the
relative effectiveness of the three treatments across the binary subgroup levels (unadjusted due to low number of events). †To achieve this P value one participant, with a PSA > 10
ng/mL and receiving radical radiotherapy, was recoded as dying from PCa to avoid a zero numerator. ‡ISUP Grade Group-derived sum of primary and highest Gleason grade of
secondary and tertiary. §Defined as ‘low’ if Grade Group = 1 and PSA ≤ 10 ng/mL and T1c/T2a, ‘high’ if Grade Group ≥4 or PSA >20 ng/mL or T2c, ‘intermediate’ if Grade
Group = 2/3 or 10 < PSA≤20 ng/mL or T2b.
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screening, followed by TRUS-guided biopsies, detected many
low-risk cancers, but also missed lethal cases [25]. Second, the
ProtecT AM protocol was less intensive than contemporary
AS regimes, although no current method has been validated
to improve long-term clinical outcomes. Third, there were
very few participants with high-risk disease at baseline (3%).
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Fig. 1 Cumulative incidence of disease progression by International Society of Urological Pathology Grade Group (GG) and clinical stage, based on
intention to treat groups. AM, active monitoring.
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Fig. 2 Cumulative incidence of disease progression by age and PSA level, based on intention-to-treat groups. AM, active monitoring.
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Fourth, we recognize that the ProtecT cohort under-
represents the racial diversity seen in other more global
practices, particularly for African-Caribbean men who
comprised only 2% of ProtecT participants. The lack of racial
diversity of the ProtecT trial, which reflects the ethnic
composition of the UK recruiting centres, has been raised in
previous publications [26].
The main strengths of ProtecT are threefold. First, its size,
with over 82 000 tested individuals, second the standardized
diagnostic approach that was employed widely in Europe
prior to recent pre-biopsy mpMRI introduction (and which is
still used in many parts of the USA), and third, the high
randomization rate of men enrolled to ProtecT [27].
The findings of this study differ from those of registry-based
data, such as those in the Surveillance, Epidemiology, and
End Results (SEER) programme in the USA, as the ProtecT
trial is an RCT of treatment effectiveness for localized PCa,
embedded within a trial of PSA-based screening. Moreover,
participants in ProtecT have ongoing clinical follow-up, with
the median 15-year follow-up data to be reported in the next
2 years. SEER, and similar Scandinavian registries, are
observational series rather than RCTs, therefore ProtecT
provides us with a unique insight into the baseline clinic-
pathological features of patients who progress, vs those who
do not progress, after long-term follow-up following
treatment intervention in the context of an RCT.
None of the 174 ProtecT participants with pathological Grade
Group 1 after undergoing RP progressed, suggesting surgery
cures definite low-risk Grade Group 1 disease. This probably
represents over-treatment of disease that would not have
progressed if simply observed. If accurately identified, such
patients may benefit from AM and avoid treatment side
effects without deleterious oncological outcomes, as advocated
in AS protocols [28,29].
The absence of any association between the number of
tumour foci in the RP specimen and disease progression
contrasts with data suggesting multifocal disease is associated
with increased recurrence risk [30]. Evidence from ProtecT
suggests solitary tumours were found in only one-fifth of RP
specimens with PSA-detected localized disease [31].
In conclusion, baseline clinico-pathological features of men
with localized PCa within ProtecT were associated with
disease progression, but these associations were not strong
enough to reliably predict individual progression. As the
genomic diversity of PCa is elucidated, it is becoming clear
that stratification methods need refinement with pre-biopsy
imaging and targeted sampling, alongside utilisation of
Table 3 Hazard ratios for disease progression by surgical pathological characteristics in participants who were randomized to and received radical
prostatectomy within 1 year. [Correction added on 05 March 2020, after first online publication: Table 3 has been amended in this version.]
Surgical
characteristic
Category N (%) No
progression
(n = 378)
n (%)
Progression
outcome
(n = 19)
n (%)
HR (95% CI); P value Metastasis
and/ or
PCa-specific
death (n = 7)
n (%)
HR (95% CI);
P value *
ISUP Grade Group† 1 196 (50) 196 (100) 0 (0) 0 (0)
2 162 (41) 154 (95) 8 (5) <0.001† 2 (1) <0.001‡
3+ 36 (9) 25 (69) 11 (31) 5 (14)
Pathological stage pT2 275 (70) 273 (99) 2 (1) – 0 (0) –
pT3/T4 117 (30) 100 (85) 17 (15) 22.01 (5.02, 96.50); <0.001 7 (6) <0.001‡
Largest tumour
volume, n = 305
Median (IQR) 0.8 (0.3, 1.9) 4.0 (2.1, 5.6) 1.23 (1.11, 1.36); <0.001 4.1 (2.3, 5.6) 1.22 (1.04, 1.43); <0.001
Number of
tumours
One 76 (19) 71 (93) 5 (7) 2 (3) –
Multiple 315 (81) 301 (96) 14 (4) 0.72 (0.26, 1.99); 0.524 5 (2) 0.66 (0.13, 3.42); 0.623
Involvement of
lymph nodes
Negative 290 (99) 276 (95) 14 (5) – 4 (1) –
Positive 4 (1) 1 (25) 3 (75) 22.77 (6.36, 81.49); <0.001 2 (50) 85.12 (11.46, 632.10); <0.001
Extraprostatic
perineural
invasion
No 278 (71) 275 (99) 3 (1) – 0 (0) –
Yes 112 (29) 96 (86) 16 (14) 14.38 (4.15, 49.87); <0.001 7 (6) <0.001‡
Vascular invasion No 383 (98) 369 (96) 14 (4) – 5 (1) –
Yes 8 (2) 3 (38) 5 (63) 26.39 (9.11, 76.50); <0.001 2 (25) 17.05 (3.22, 90.36); 0.001
Positive margins No 270 (68) 262 (97) 8 (3) – 4 (1) –
Yes 127 (32) 116 (91) 11 (9) 2.89 (1.16, 7.19); 0.023 3 (2) 1.41 (0.31, 6.35); 0.657
Upgraded‡ No 257 (69) 253 (98) 4 (2) – 1 (<1) –
Yes 116 (31) 110 (95) 6 (5) 3.40 (0.96, 12.112); 0.059 2 (2) 4.32 (0.39, 47.75); 0.233
Upstaged§ No 275 (70) 273 (99) 2 (1) – 0 (0) –
Yes 117 (30) 100 (85) 17 (15) 22.01 (5.02, 96.50); <0.001 7 (6) <0.001‡
ISUP, International Society of Urological Pathology; PCa, prostate cancer. *Cox models for time to progression, adjusting for age at randomization. †ISUP Grade Group-derived sum
of radical prostatectomy Gleason primary and secondary grades. ‡Low number of events so log rank test. ‡Defined as Grade Group 1 to >Grade Group 1 or Grade Group 2 to
≥Grade Group 3, with the denominator equal to those with Grade Group 1 or Grade Group 2 at baseline. §Defined as T1/T2 to T3/T4 disease, with the denominator equal to those
with T staging of T1 or T2 at baseline.
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validated genomic and other emerging biomarkers. This will
need to be assessed in large-scale prospective early detection
programmes. Only then will clinicians and patients be able to
refine the complex decision-making processes needed to
manage this ubiquitous malignancy.
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